Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | ASPH | Q12797 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 3/20 | 0.41 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.38 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19585173 | 0.88 | DAO (0.44) | KDM4EALDH1A1HPGDHSD17B10DAO | |
| SCHEMBL2320900 | 0.84 | ALB (0.46) | KDM4EALDH1A1HPGDHSD17B10DAO | |
| SCHEMBL1235350 | 0.82 | TAS2R14 (0.49) | KDM4EALDH1A1HPGDHSD17B10DAO | |
| SCHEMBL30294676 | 0.82 | CLCN2 (0.49) | KDM4EALDH1A1HPGDHSD17B10DAO | |
| SCHEMBL30634615 | 0.82 | TAS2R14 (0.45) | KDM4EALDH1A1HPGDHSD17B10DAO | |
| SCHEMBL1634606 | 0.82 | TAS2R14 (0.45) | KDM4EALDH1A1HPGDHSD17B10DAO | |
| SCHEMBL19893742 | 0.82 | CLCN2 (0.46) | KDM4EALDH1A1HPGDHSD17B10DAO | |
| SCHEMBL30548341 | 0.82 | CYP1A2 (0.58) | KDM4EALDH1A1HPGDHSD17B10ASPH | |
| SCHEMBL1713540 | 0.82 | CYP1A2 (0.58) | KDM4EALDH1A1HPGDHSD17B10ASPH | |
| SCHEMBL5025538 | 0.82 | CES2 (0.40) | KDM4EALDH1A1HPGDHSD17B10CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197399-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| EP-4499626-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Nico Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119233972-A | Compounds, compositions, and methods | 尼科治疗有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-20240254132-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TENVIE THERAPEUTICS, INC. | 2024-08-01 | — | — | US | disclosed |
| EP-4370110-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| CN-114269756-B | 4-Oxo-3, 4-dihydropyrido [3,4-D ] pyrimidine compounds that inhibit EIF4E | 效应疗法股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117940120-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4330236-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| WO-2023192390-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-1937675-B1 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS (FR) | 2011-06-22 | — | — | EP | disclosed |
| WO-2011036074-A1 | AMINOQUINAZOLINE COMPOUNDS FOR COMBATING INVERTEBRATE PESTS | BASF SE (DE) | 2011-03-31 | — | — | WO | disclosed |
| US-7772257-B2 | Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation, pharmaceutical compositions and methods for their use | SANOFI-AVENTIS (FR) | 2010-08-10 | — | — | US | disclosed |
| US-20100022603-A1 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | SANOFI-AVENTIS (FR) | 2010-01-28 | — | — | US | disclosed |
| US-7612104-B2 | Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation, pharmaceutical compositions and methods for their use | SANOFI-AVENTIS (FR) | 2009-11-03 | — | — | US | disclosed |
| US-20080293780-A1 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | SANOFI-AVENTIS (FR) | 2008-11-27 | — | — | US | disclosed |
| EP-1937675-A2 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007039174-A2 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293780-A1 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | PPARG, PPARA, PPARD | KDM4E 3260/4885ALDH1A1 1019/4885HPGD 1304/4885 |
| US-20100022603-A1 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | PPARG, PPARA, PPARD | KDM4E 3386/4885ALDH1A1 1072/4885HPGD 1298/4885 |
| US-20240254132-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | NLRP3, NLRP1, NOD1 | KDM4E 3928/4885ALDH1A1 4692/4885HPGD 3378/4885 |
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NLRP3, NLRP1, NOD1 | KDM4E 3822/4885ALDH1A1 4711/4885HPGD 3426/4885 |
| US-20250197399-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NLRP3, NLRP1, NOD1 | KDM4E 3822/4885ALDH1A1 4711/4885HPGD 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.